A Single-Dose, Randomized, Open-Label, 2-Way Crossover Study to Evaluate the Dose-Proportionality, Safety, and Tolerability of TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets) in Healthy Japanese and Chinese Subjects

Clinical trial NCT07464535 · COMPLETED

Trial details

NCT number: NCT07464535
Sponsor: Tonix Pharmaceuticals, Inc.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Healthy Subjects (HS)

Start date: 2022-03-18
Primary completion: 2022-04-30
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.